ArticleFunctional & integrative genomics2026
NeuroMetBench: patient-aware evidence bounds for transcript-derived metabolic representations across cancer proteogenomic contexts.
Article in Functional & integrative genomics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Transcript-derived metabolic representations connect gene expression with pathway state, but interpretation depends on sampling unit, endpoint, cohort, and validation evidence. NeuroMetBench is a patient-aware methodology that keeps target quantity, independent unit, endpoint mapping, coverage, uncertainty, transport, numerical diagnostics, and provenance separate rather than collapsing them into a universal score. A frozen three-gene serine score showed RNA-protein rank concordance in 89 lung squamous cell carcinoma (LSCC) patients (Spearman [Formula: see text], 95% confidence interval (CI) 0.8496 to 0.9388) and in a patient-disjoint 90-patient central nervous system/high-grade-glioma (CNS/HGG) cohort ([Formula: see text], 95% CI 0.4697 to 0.7507). Reviewer-driven age/sex sensitivities remained positive in complete cases (LSCC [Formula: see text], partial [Formula: see text]; CNS/HGG [Formula: see text], partial [Formula: see text]), but CNS/HGG complete-case selection was associated with the frozen RNA-score distribution and cannot rule out demographic confounding. A preanalysis-frozen Tel Aviv glioblastoma test was NOT RUN because public RNA/proteomics deposits yielded zero source-documented patient cross-matches (minimum [Formula: see text]). A separately frozen Sun Yat-sen University Cancer Center (SYSUCC) analysis found 20 exact RNA/protein-matched glioblastomas and positive concordance ([Formula: see text], 95% CI 0.1252 to 0.9101; permutation [Formula: see text]). By contrast, RNA score correspondence with measured L-serine in 75 same-cohort patients was weak and uncertain ([Formula: see text], 95% CI -0.0803 to 0.3737; permutation [Formula: see text]). Evidence strength is therefore axis-specific: cross-modal proxy concordance does not establish metabolic flux, biochemical validation, universal method superiority, framework-wide external validation, or calibration.
Indexed as
Identifiers
42888333What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.